Table 2.

primary endpoint analysis at W48 of the 382 patients switching to E/C/F/TDF

	Present study n = 382	S trategy–PI Arribas et al. [9] n = 290	Strategy– NNRTI Pozniak et al. [10] n = 290
Success (patients with VL < 50 copies/mL at W48)	314 (82.0) [95% CI 78.4–86.0]	272 (94.0)	271 (93.0)
Virologic failure (VL ≥ 50 copies/mL at W48)	13(3.5%) [95% CI 3.64–8.41]	2 (1.0)	3 (1.0)
Genotype available at failure	6/13	0 (0.0)	1
Resistance to INSTIs	5/6	0 (0.0)	0
No data	55 (14.5) 95% CI 10.9–17.9]	16 (6.0)	16 (6.0)
Adverse events leading to treatment discontinuation	23 (6.0) [95% CI 3.6–8.4]	6 (2.0)	6 (2.0)
Other reasons for treatment discontinuation and lost to follow–up	31 (8.2)* [95% CI 5.6–11.4]	11 (3.8)	11 (3.8)
Death	1 (0.3) [95% CI 0.0–1.7]	0 (0.0)	1 (0.3)
Total	382 (100.0)	290 (100.0)	290 (100.0)

Data are n (%) [95% CI]

INSTI integrase strand transfer inhibitor

*Lost to follow-up (n = 16), patient’s decision (n = 4), drug-drug interaction (n = 3), pregnancy (n = 3), unknown reason (n = 3), toxicity prevention (n = 1), end of treatment (n = 1)